Compare Divis Laboratories with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ELDER PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ELDER PHARMA DIVIS LABORATORIES/
ELDER PHARMA
 
P/E (TTM) x 52.0 -0.2 - View Chart
P/BV x 12.0 0.1 11,864.7% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 DIVIS LABORATORIES   ELDER PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
ELDER PHARMA
Jun-14
DIVIS LABORATORIES/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639380 431.4%   
Low Rs1,115188 593.1%   
Sales per share (Unadj.) Rs186.3491.2 37.9%  
Earnings per share (Unadj.) Rs51.0-3.2 -1,601.6%  
Cash flow per share (Unadj.) Rs57.314.4 397.8%  
Dividends per share (Unadj.) Rs16.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs261.8376.5 69.5%  
Shares outstanding (eoy) m265.4720.54 1,292.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.40.6 1,278.4%   
Avg P/E ratio x27.0-89.3 -30.3%  
P/CF ratio (eoy) x24.019.7 121.9%  
Price / Book Value ratio x5.30.8 697.4%  
Dividend payout %31.40-   
Avg Mkt Cap Rs m365,5925,833 6,267.3%   
No. of employees `00011.8NA-   
Total wages/salary Rs m5,4232,179 248.9%   
Avg. sales/employee Rs Th4,175.1NM-  
Avg. wages/employee Rs Th457.7NM-  
Avg. net profit/employee Rs Th1,141.8NM-  
INCOME DATA
Net Sales Rs m49,46310,089 490.3%  
Other income Rs m1,556257 606.5%   
Total revenues Rs m51,01910,346 493.1%   
Gross profit Rs m18,718-792 -2,363.7%  
Depreciation Rs m1,689361 467.5%   
Interest Rs m352,756 1.3%   
Profit before tax Rs m18,551-3,653 -507.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m5,023125 4,013.8%   
Profit after tax Rs m13,527-65 -20,699.9%  
Gross profit margin %37.8-7.8 -482.1%  
Effective tax rate %27.1-3.4 -790.4%   
Net profit margin %27.3-0.6 -4,222.2%  
BALANCE SHEET DATA
Current assets Rs m46,5019,240 503.3%   
Current liabilities Rs m8,4689,998 84.7%   
Net working cap to sales %76.9-7.5 -1,023.9%  
Current ratio x5.50.9 594.2%  
Inventory Days Days13146 282.5%  
Debtors Days Days8660 143.2%  
Net fixed assets Rs m25,79710,124 254.8%   
Share capital Rs m531206 258.1%   
"Free" reserves Rs m68,9625,582 1,235.4%   
Net worth Rs m69,4937,734 898.6%   
Long term debt Rs m04,889 0.0%   
Total assets Rs m80,38322,882 351.3%  
Interest coverage x531.0-0.3 -163,244.5%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.4 139.6%   
Return on assets %16.911.8 143.5%  
Return on equity %19.5-0.8 -2,303.6%  
Return on capital %26.722.3 119.9%  
Exports to sales %03.0 0.0%   
Imports to sales %24.60.4 5,767.5%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs m12,18743 28,275.6%   
Fx inflow Rs m41,238307 13,450.0%   
Fx outflow Rs m12,405125 9,900.3%   
Net fx Rs m28,833181 15,903.2%   
CASH FLOW
From Operations Rs m9,54311,754 81.2%  
From Investments Rs m-6,854-561 1,222.8%  
From Financial Activity Rs m-2,459-6,762 36.4%  
Net Cashflow Rs m2304,432 5.2%  

Share Holding

Indian Promoters % 52.0 39.6 131.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 7.5 157.3%  
FIIs % 19.0 16.8 113.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 36.1 47.6%  
Shareholders   31,796 16,479 192.9%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   FRESENIUS KABI ONCO.  CADILA HEALTHCARE  ALKEM LABORATORIES  DR. REDDYS LAB  SANOFI INDIA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Crashed 600 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended their session deep in the red.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

Why ITC and not HUL is my Idea of a Good Investment Right Now(Views On News)

Oct 15, 2020

Rahul Shah discusses HUL's lost decade and its implications for ITC.

PSU Banks Will Move Up Again(Profit Hunter)

Oct 27, 2020

My charts tell me PSU banks are set for a rebound.

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Oct 28, 2020 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - GLENMARK PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS